Inflammasome's K8 slows geographic atrophy 54% in small Phase 2 study
A 30-patient trial found K8 outpaced the two approved GA drugs' six-month growth-slowing benchmark, but the readout rests on one dose cohort and a subgroup analysis.
Executive Summary
- A Phase 1/2 study of K8 in geographic atrophy completed and reported that its mid-dose cohort slowed lesion growth substantially more than the two currently approved treatments have shown in comparable six-month windows.
- The trial also reported a visual-acuity advantage in eyes with lesions away from the central retina, a benefit neither approved GA therapy demonstrated in its own pivotal trials.
- The trial was small, unmasked, and compared treated eyes to a pooled control and the untreated fellow eye rather than a randomized placebo arm, and the headline effect size comes from one of three dose groups rather than the whole study.
- The sponsor plans to move into a global Phase 3 pivotal program and engage regulators, which would be the first test of whether the effect holds under a randomized, controlled design.
The result
Inflammasome Therapeutics said its 0.7 mg dose of K8, a dual inflammasome inhibitor delivered as a bioerodible intravitreal implant, produced a 54% lower mean rate of GA lesion growth than pooled control over six months (p=0.016, using the FDA-preferred slope analysis). The company separately reported a prespecified analysis in eyes with lesions outside the central retina, showing a 4.0-ETDRS-letter advantage in best-corrected visual acuity for K8-treated eyes versus control eyes (p=0.004). It said no safety signals emerged through six months. InflammasomeInflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic AtrophyJul 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
The multicenter US trial, registered as NCT06164587, enrolled 30 participants with bilateral GA across nine centers, for 60 eyes total. Each participant's worse-seeing eye received a K8 implant while the fellow eye remained untreated, and the study tested three doses, 0.3 mg, 0.7 mg, and 1.05 mg, given at baseline and repeated at Month 3, in an open-label, single-arm design with no masking of treatment assignment. Imaging for the primary lesion-growth endpoint was read by masked graders at an independent center, and the trial listed ten primary outcome measures spanning growth on multiple imaging modalities, visual acuity, reading speed, and adverse events, plus one secondary endpoint tracking visual acuity over time. The trial completed on May 15, 2026, and its status moved from active to completed on July 2, 2026. NCT06164587Evaluation of Kamuvudine-8 in Subjects With Geographic AtrophyNCT06164587
Against the benchmark
Inflammasome framed the 54% figure against the two drugs already approved for GA: avacincaptad pegol (Izervay) and pegcetacoplan (Syfovre), both complement inhibitors indicated for geographic atrophy secondary to age-related macular degeneration. The company said those drugs reduced the mean rate of GA growth by roughly 13% to 14% versus controls over the same six-month window in their own trials, and that neither showed a visual-acuity benefit. Inflammasome acknowledged the comparison is not head-to-head. Geographic atrophy has no approved therapy that has demonstrated a vision benefit to date, so a result pairing a larger anatomic effect with a visual-acuity signal, even from a subgroup, addresses a gap the two approved drugs left open. InflammasomeInflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic AtrophyJul 17, 2026
What the design limits
A 30-patient, open-label, single-arm study comparing treated eyes to pooled controls and untreated fellow eyes is hypothesis-generating rather than decision-grade. The 54% figure applies to one of three dose cohorts, and the visual-acuity finding applies only to a prespecified subset of eyes with lesions away from the fovea, not the full enrolled population. The trial's primary completion date shifted five times over its life, moving from an original October 2024 target to May 2026, alongside a planned enrollment increase from 5 to 30 participants recorded in the registry, changes that reflect an early-phase study scaling and rescheduling rather than a readout at risk, since enrollment finished at its 30-patient target with no shortfall. NCT06164587Evaluation of Kamuvudine-8 in Subjects With Geographic AtrophyNCT06164587
The field
The active competitive set for GA spans mechanisms rather than converging on one: complement inhibitors already approved, an anti-FAS-receptor agent (ONL Therapeutics' ONL1204), a gene therapy raising CD59 (Janssen's JNJ-81201887), and RBP4-targeting Tinlarebant from Belite Bio in Phase 3, among others in earlier testing. None of the trials Inflammasome's own dossier surfaces shares K8's target, so this readout sits as a distinct entry in a mechanistically varied field rather than a comparator study against a specific rival. With no disease-modifying mechanism yet shown to also preserve vision, the bar the K8 program faces in a controlled Phase 3 is replicating both the growth-slowing magnitude and the visual-acuity signal together, and doing so under randomization and masking rather than pooled and fellow-eye comparisons.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.